Published in Heart on May 13, 2007
A panel of neuron-enriched proteins as markers for traumatic brain injury in humans. J Neurotrauma (2009) 1.39
Serum neuron-specific enolase as predictor of outcome in comatose cardiac-arrest survivors: a prospective cohort study. BMC Cardiovasc Disord (2011) 1.06
S-100B and neuron-specific enolase as predictors of neurological outcome in patients after cardiac arrest and return of spontaneous circulation: a systematic review. Crit Care (2009) 1.06
Changes in S-100 protein serum levels in survivors of out-of-hospital cardiac arrest treated with mild therapeutic hypothermia: a prospective, observational study. Crit Care (2009) 1.05
S100 protein family and its application in clinical practice. Hippokratia (2008) 1.03
Mild therapeutic hypothermia shortens intensive care unit stay of survivors after out-of-hospital cardiac arrest compared to historical controls. Crit Care (2008) 0.98
Estimated cerebral oxyhemoglobin as a useful indicator of neuroprotection in patients with post-cardiac arrest syndrome: a prospective, multicenter observational study. Crit Care (2014) 0.94
Coma due to cardiac arrest: prognosis and contemporary treatment. F1000 Med Rep (2009) 0.84
Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia. PLoS One (2014) 0.83
MicroRNAs: new biomarkers and therapeutic targets after cardiac arrest? Crit Care (2015) 0.80
The Modified Glasgow Outcome Score for the prediction of outcome in patients after cardiac arrest: a prospective clinical proof of concept study. Clin Res Cardiol (2012) 0.77
Serum neuron specific enolase and malondialdehyde in patients after out-of-hospital cardiac arrest. Cell Mol Neurobiol (2009) 0.77
Therapeutic effects of various methods of MSC transplantation on cerebral resuscitation following cardiac arrest in rats. Mol Med Rep (2016) 0.76
Effect of Tempol on Cerebral Resuscitation Caused by Asphyxia-Induced Cardiac Arrest. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2015) 0.75
The hospital anxiety and depression scale. Acta Psychiatr Scand (1983) 121.58
Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex (1978) 4.78
"Heartstart Scotland"--initial experience of a national scheme for out of hospital defibrillation. BMJ (1991) 4.56
Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome for comatose survivors of cardiac arrest. JAMA (2004) 3.80
Prediction of poor outcome within the first 3 days of postanoxic coma. Neurology (2006) 2.46
Predictive value of somatosensory evoked potentials for awakening from coma. Crit Care Med (2003) 2.44
In-hospital mortality after out-of-hospital cardiac arrest. Lancet (1995) 2.37
Sudden cardiac death. I. A decade's experience with out-of-hospital resuscitation. Mod Concepts Cardiovasc Dis (1980) 2.30
The development and validation of a test battery for detecting and monitoring everyday memory problems. J Clin Exp Neuropsychol (1989) 1.98
Serum neuron-specific enolase and S-100B protein in cardiac arrest patients treated with hypothermia. Stroke (2003) 1.67
Outcome after cardiac arrest: predictive values and limitations of the neuroproteins neuron-specific enolase and protein S-100 and the Glasgow Coma Scale. Resuscitation (2005) 1.53
The neurological and cognitive sequelae of cardiac arrest. Neurology (2004) 1.28
Serum S-100 and neuron-specific enolase for prediction of regaining consciousness after global cerebral ischemia. Stroke (1998) 1.23
Serum levels of the brain-derived proteins S-100 and NSE predict long-term outcome after cardiac arrest. Resuscitation (2001) 1.20
Serum neuron-specific enolase as early predictor of outcome after cardiac arrest. Crit Care Med (1997) 1.08
Prediction of outcome in patients with anoxic coma: a clinical and electrophysiologic study. Crit Care Med (1996) 1.03
Serum neuron-specific enolase predicts outcome in post-anoxic coma: a prospective cohort study. Intensive Care Med (2002) 1.02
Increased serum levels of the S-100 protein are associated with hypoxic brain damage after cardiac arrest. Stroke (1998) 1.01
Serum neuron-specific enolase as a prognostic marker for irreversible brain damage in comatose cardiac arrest survivors. Acad Emerg Med (1996) 0.98
Serum neuron-specific enolase, carnosinase, and their ratio in acute stroke. An enzymatic test for predicting outcome? Stroke (1996) 0.97
Chronic memory impairment after cardiac arrest outside hospital. BMJ (1996) 0.94
The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer (1998) 0.94
Elevated serum levels of S-100 after deep hypothermic arrest correlate with duration of circulatory arrest. Eur J Cardiothorac Surg (1996) 0.87
Out-of-hospital resuscitation in Tartu: effect of reorganization of Estonian EMS system. Am J Emerg Med (2000) 0.86
Outcomes and in-hospital treatment of out-of-hospital cardiac arrest patients resuscitated from ventricular fibrillation by early defibrillation. Mayo Clin Proc (2004) 0.80
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 17.19
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med (2007) 7.96
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med (2003) 7.25
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation (2003) 5.70
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24
Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA (2010) 5.10
Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72
Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2003) 4.70
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49
Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10
Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol (2012) 3.93
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med (2006) 3.56
Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA (2011) 3.56
Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol (2002) 3.45
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet (2004) 3.40
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J (2002) 3.36
Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation (2006) 3.22
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet (2012) 3.19
International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation (2007) 3.01
Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J (2005) 2.94
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation (2002) 2.89
Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation (2002) 2.89
Potential impact of public access defibrillators on survival after out of hospital cardiopulmonary arrest: retrospective cohort study. BMJ (2002) 2.89
Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation (2010) 2.88
Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med (2004) 2.80
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77
Differences in the management and prognosis of women and men who suffer from acute coronary syndromes. J Am Coll Cardiol (2005) 2.76
Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. Eur J Heart Fail (2013) 2.73
Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure. Eur J Heart Fail (2012) 2.72
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol (2003) 2.54
Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation (2004) 2.33
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation (2003) 2.20
Public health in community pharmacy: a systematic review of pharmacist and consumer views. BMC Public Health (2011) 2.19
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA (2005) 2.17
Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. Eur Heart J (2008) 2.16
Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol (2009) 2.16
Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation (2005) 2.13
Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation (2007) 2.12
Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. Ann Surg (2010) 2.06
Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation (2003) 2.05
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation (2008) 2.05
Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: cohort study. BMJ (2012) 2.02
Reperfusion strategy in Europe: temporal trends in performance measures for reperfusion therapy in ST-elevation myocardial infarction. Eur Heart J (2010) 2.01
Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras. Circ Heart Fail (2011) 1.96
A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: the GRACE Genetics Study. Eur Heart J (2010) 1.90
Diesel exhaust inhalation does not affect heart rhythm or heart rate variability. Heart (2010) 1.84
Leptin is an endothelial-independent vasodilator in humans with coronary artery disease: Evidence for tissue specificity of leptin resistance. Eur Heart J (2006) 1.81
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol (2007) 1.75
Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J (2011) 1.71
Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J Am Coll Cardiol (2002) 1.67
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J (2008) 1.65
Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J (2008) 1.64
Post-discharge survival following pre-hospital cardiopulmonary arrest due to cardiac aetiology: temporal trends and impact of changes in clinical management. Eur Heart J (2005) 1.59
Adipocytokines and risk of stroke in older people: a nested case-control study. Int J Epidemiol (2008) 1.59
The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. Int J Epidemiol (2011) 1.58
The expanded Global Registry of Acute Coronary Events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. Am Heart J (2009) 1.57
Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block: GRACE (Global Registry of Acute Coronary Events). JACC Cardiovasc Interv (2009) 1.56
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. Eur Heart J (2004) 1.55
Cost-effectiveness of automated external defibrillators in public places: con. Curr Opin Cardiol (2007) 1.54
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J (2013) 1.53
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J (2008) 1.52
Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation (2002) 1.51
The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur Heart J (2009) 1.49
Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. Am Heart J (2009) 1.47
Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol (2002) 1.47
Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: A double-blind, randomized, placebo-controlled study. Am Heart J (2004) 1.45
Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J (2008) 1.44
Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. Am J Cardiol (2003) 1.44
Increased mortality in parents bereaved in the first year of their child's life. BMJ Support Palliat Care (2011) 1.44
Microvolt T-wave alternans testing has no role at present in guiding therapy for patients at high risk of ventricular arrhythmias. J Am Coll Cardiol (2012) 1.44
C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation (2007) 1.43
Nice guidance on the investigation of chest pain. Heart (2010) 1.43